Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11362MR)

This product GTTS-WQ11362MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11362MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10186MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ11495MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ7710MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ8093MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ14133MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ12547MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ650MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ2247MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALX-0171
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW